Guardian Research Network, Inc.® (GRN) and ThinkGenetic, Inc. announce a strategic collaboration to accelerate the diagnosis and support the development of treatment options for patients with rare and genetic diseases.
ThinkGenetic, Inc. announces the official acceptance of a $500,000 investment from the Ochsner Lafayette General Healthcare Innovation Fund.
ThinkGenetic, Inc. is set to launch three disease-specific versions of the diagnostic aid, SymptomMatcher™ for upcoming pilot awareness initiatives by global biopharmaceutical leader, Takeda Pharmaceutical Company Limited.
ThinkGenetic, Inc., makers of an artificial intelligence-driven SymptomMatcher™ for genetic disorders, today announced the successful close of its angel round of funding for $1.5M.
Most medical treatments fall into four broad categories based on their goal: For the most part, treatments for genetic diseases have fallen into the preventive, disease management, or palliative categories. […]